Bezos Earth Fund Announces $24.5 Million for Coastal Protection and Stewardship Across the Eastern Tropical Pacific New grants support community-led stewardship and advance science-driven decision-making across Costa Rica, Panama, Colombia and Ecuador GlobeNewswire December 09, 2025 WASHINGTON, Dec. 09, 2025 (GLOBE NEWSWIRE) — The Bezos Earth Fund today announced $24.5 million in grants to help […]

LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding. In addition, Relation is eligible to receive preclinical, development,

London, UK – 9th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, will once again support the International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders (SCWD) taking place in Rome, Italy

LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA's venture capital arm) and leading deeptech investors DCVC and Magnetic Ventures. “Relation's unique combination of computation, experimentation, and patient data will reduce failure rates in drug development and transform the way we treat common, devastating

Breakthrough enables scalable, high-precision biosensing applications in life sciences and healthcare https://mma.prnewswire.com/media/2839859/imec_Logo.jpg — Imec has achieved the first successful wafer-scale fabrication of solid-state nanopores using EUV lithography on 300mm wafers. This innovation transforms nanopore technology from a lab-scale concept into a scalable platform for biosensing, genomics and proteomics. — Nanopores are hailed as gamechangers for

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases GlobeNewswire December 09, 2025 LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 million, comprising an upfront

Relation announces further $26 million investment GlobeNewswire December 09, 2025 LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) — Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA's venture capital arm) and leading deeptech investors DCVC and Magnetic Ventures. “Relation's unique combination of computation, experimentation, and patient data will reduce failure rates in

Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders GlobeNewswire December 09, 2025 London, UK – 9th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other

As the world's first country to be prescribed for its health benefits, Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy. The Swedish Prescription video shows how it works. https://mma.prnewswire.com/media/2838648/Northern_lights_Visit_Sweden_AB.jpg With interest in “northern lights travel” on the rise and 61% of

Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as neoadjuvant therapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was presented at the 2025 ESMO Asia Congress. Currently, Akeso is running the